Weight loss – the formoline L112 advantages

Lipid adsorbent to:

support reduce excess weight
support long-term weight control
lower cholesterol intake from diet

Product key facts

The No. 1* slimming tablet in Germany
Multiple award and prize winner
Successfully launched in more than
40 countries worldwide
Good tolerability and low side effect profile
Medical Device Class III certified by a
designated Notified Body

Slimming Slimming Slimming Slimming Slimming

product product product product product
of the year 2015
of the year 2013
**
of the year 2012
**
of the year 2011
**
of the year 2010**
**

Bundesverband Deutscher
Bundesverband Deutscher
Bundesverband Deutscher
Bundesverband Deutscher
Bundesverband Deutscher
Apotheker e. V. Apotheker e. V. Apotheker e. V. Apotheker e. V. Apotheker e. V.

*A.C. Nielsen „Top Marken Diätetika 2013, Solid Oral Dosage Forms only“
**Awards translated into English: “Schlankheitsmittel des Jahres 2015”, “Schlankheitsmittel des Jahres 2013”, “Schlankheitsmittel des Jahres 2012“,
“Schlankheitsmittel des Jahres 2011”, “Schlankheitsmittel des Jahres 2010”.
 Effectiveness & Safety

Reduction of lipid absorption into the blood by 66 %

The reduced uptake of calories from
12 the dietary fats has been confirmed
µg/g Blood plasma

in an in vivo placebo-controlled
8 study. The study was carried out
on two parallel treatment groups,
4 each consisting of six adult female
Göttingen minipigs. One group served
0 as the untreated placebo group
0 4 8 12 Hours (control) and the other group was
pre-treated with 2 tablets of 500 mg
Lipid content without formoline L112 formoline L112.
Lipid content with formoline L112
Cnubben N. H. P. et al. (2016): A single oral dose of
a polyglucosamine influences the bioavailability
Lipids from food fats in the blood plasma with and without formoline L112
of [9-14C]-Oleic acid in adult female Göttingen
minipigs. BMC Obesity 3(1):1-12.

Average weight loss 6.7 kg

The randomised, double-blind,
clinical study with 64 patients
102
Mean Body Weight (kg)

shows that the medical device

polyglucosamine (formoline L112) 100
98 formoline L112
is significantly more effective than
non-prescription drug orlistat 96
60 mg in weight reduction. With 94 orlistat
formoline L112 (polyglucosamine)
92
subjects lost 6.7 kg on average 0 2 4 6 8 10 12
during three months.
Study (Weeks)
Stoll M., et al. (2016): Randomised, double-­
FLF1702EN

blind, clinical investigation to compare orlistat

60 mg and a customized polyglucosamine, two Weight loss by treatment with polyglucosamine (L112)
treatment methods for the management of
overweight and obesity. BMC Obesity (2017) 4:4.

Manufacturer: Certmedica International GmbH For more information:

Magnolienweg 17, 63741 Aschaffenburg, Germany
www.certmedica.de www.L112.com